Ansøgningsnr. og dato | 17753704.0 (espacenet) (Federated) (European Patent Register), 20170214 | Patent/reg.nr. og dato | DK/EP 3417294, 20211201 | Tilgængelighedsdato | 20181226 | Prioritetsnr. og dato | US 201662295421 P, 20160215 | EP publ. nr. og dato |
EP 3417294 20181226 | Løbedag | | Ansøger/indehaver | Astrazeneca AB, 151 85 Södertälje, SE, The United States of America, as Represented By the Secretery, Department of Health and Human Services, Office of Technology Transfer 6701 Rockledge Drive Suite 700, MSC 7788 Bethesda, MD 20892 / US, US | Ansøgers ref. nr. | 1625291 | Opfinder | BARRY, Simon, AstraZeneca Darwin Building Cambrige Science Park Milton Road
Cambridge CB4 0WG, GB, KENDREW, Jane, AstraZeneca Alderley Park
Macclesfield Cheshire SK10 4TG, GB, HO, Tony, AstraZeneca Pharmaceuticals LP One Medlmmune Way
Gaithersburg, MD 20878, US, WEDGE, Stephen, Robert, AstraZeneca Riverside Buildnig 2
Granta Park Cambridge CB21 6GH, GB, KOHN, Elise, National Institutes of Health 6011 Executive Boulevard Suite 325 MSC 7660
Bethesda, MD 20892-7660, US, LEE, Jung-Min, National Institutes of Health 6011 Executive Boulevard Suite 325 MSC 7660
Bethesda, MD 20892-7660, US, IVY,Susan Percy, National Institutes of Health 6011 Executive Boulevard Suite 325 MSC 7660
Bethesda, MD 20892-7660, US | Fuldmægtig | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | Interessent på tilknyttet sag | | IPC-Klasse | A61K 31/502 (2006.01) , A61K 31/506 (2006.01) , A61K 38/00 (2006.01) , A61K 39/395 (2006.01) , A61K 45/06 (2006.01) , A61K 48/00 (2006.01) , A61P 35/00 (2006.01) , A61P 43/00 (2006.01) , A61P 9/10 (2006.01) , C07K 16/28 (2006.01) , G01N 33/574 (2006.01) | Titel/benævnelse | FREMGANGSMÅDER, SOM OMFATTER FAST INTERMITTERENDE DOSERING AF CEDIRANIB | Internationalt ansøgningsnr. | US2017017804 | Internationalt publ. nr. | WO2017142871 | Relateret sag (certifikat) | | Status | DK/EP patent | Pædiatrisk forlængelse | - | Udløbsdato for pædiatrisk forlængelse | - |
|